Delivery Order SPE2DB20D2104-SPE2DB25FMWLK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,535.33 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units). This firm fixed-price, competitively awarded contract was executed on August 19, 2025, with an ultimate completion date of August 20, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.50 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 5, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this medical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,956.58 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This non-set-aside, firm fixed price delivery order was competitively awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,136.82 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by August 7, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will fulfill this order from its corporate office location. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,325.02 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets in quantities of 30-count units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, ultimately due for completion on August 19, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of the contractor's pharmaceutical supply relationship with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units, with a contract ceiling value of $17,613.10. This competitively awarded, non-set-aside delivery order reflects a firm fixed-price arrangement with a completion date of September 3, 2025. The order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion master...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWLKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,401.41 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantity 30s. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, completed on July 28, 2025. The contract was issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle that runs through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs supporting military and veteran healthcare systems. This delivery order represents a routine pharmaceutical procurement under the broader Pharmaceutical Prime Vendor Global Program, which enables AmerisourceBergen Drug Corp to supply a comprehensive range of brand-name and generic medications, vaccines, and medical supplies to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. XELJANZ XR is a branded immunosuppressant medication commonly used in rheumatoid arthritis treatment. The DLA's Troop Support Medical division manages this pharmaceutical supply chain to ensure continuous availability of critical medications to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 7/25/25 |